Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

国药集团
SINOPHARM

CHINA TRADITIONAL CHINESE MEDICINE HOLDINGS CO. LIMITED
中國中藥控股有限公司

(Incorporated in Hong Kong with limited liability)
(Stock Code: 570)

CHANGE OF EXECUTIVE DIRECTOR, CHAIRMAN AND AUTHORISED REPRESENTATIVE

RESIGNATION OF EXECUTIVE DIRECTOR AND CHAIRMAN

The board (the "**Board**") of directors (the "**Directors**") of China Traditional Chinese Medicine Holdings Co. Limited (the "**Company**", together with its subsidiaries, the "**Group**") announces that the Board resolved on 17 July 2026 that Mr. YANG Jun ("**Mr. YANG**") resigned as the executive Director and the chairman of the Board as reaching the statutory retirement age, with immediate effect. Mr. YANG has also ceased to serve as chairman of each of the nomination committee (the "**Nomination Committee**") and the strategic committee (the "**Strategic Committee**") of the Board upon his resignation as the executive Director.

Mr. YANG has confirmed that he has no disagreement with the Board and there is no matter relating to his resignation that needs to be brought to the attention of the shareholders of the Company (the "**Shareholders**") and The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**").

During his tenure, Mr. YANG was diligent and prudent in his duties, and committed to enhancing corporate governance and compliance management level, thereby laying a solid foundation for the Group's long-term and sustainable development. The Board would like to take this opportunity to express its sincere gratitude to Mr. YANG for his hard work and valuable contributions.

APPOINTMENT OF EXECUTIVE DIRECTOR

The Board hereby announces that Mr. GUO Jinhong ("**Mr. GUO**") has been appointed as the executive Director, with effect from 17 July 2026. Mr. GUO will enter into an employment agreement with the Company in relation to his appointment with effect from 17 July 2026, which shall automatically be effective hereafter. He shall hold office only until the first annual general meeting of the Company after his appointment and shall then be eligible for re-election. Thereafter, he is subject to retirement by rotation and re-election in accordance with the articles of association of the Company. The remuneration of Mr. GUO will be determined by the remuneration and evaluation committee of the Board in accordance with reference to his scope of responsibilities, performance and market rate. Currently, according to the Company's remuneration policy, Mr. GUO will receive remuneration based on the performance appraisal, incentive measures and annual salary standard settlement.

The biographical details of Mr. GUO are set out below:

Mr. GUO Jinhong, aged 53, graduated from Shanxi University of Finance and Economics majoring in money and banking with a Master's degree in Economics in July 1999, and a holder of the senior auditor qualification. Mr. GUO possesses extensive experience in macroeconomic analysis, financial risk governance and corporate compliance management. He previously worked in auditing at the Taiyuan Resident Office of the National Audit Office of PRC (the "**CNAO**") and the Department of Enterprise Auditing of the CNAO, and also served as the general manager of the Audit and Supervision Department at CRCC Capital Holdings Group Corporation Limited.

Mr. GUO joined China National Pharmaceutical Group Co., Ltd. ("**CNPGC**") in February 2022, where he successively served as the director of the Audit Department and the director of Compliance Management Department (Audit & Legal Affairs) of CNPGC. Mr. GUO has been served as a supervisor of Sinopharm Group Co. Ltd. (01099.HK) since September 2023, and a member of the Commission for Discipline Inspection of CNPGC since March 2026. Mr. GUO currently also serves as the Party Secretary of the Company.

Save as disclosed above, Mr. GUO (i) does not hold any other position within the Group; (ii) has not held directorships in any other listed companies in the past three years; (iii) has not held any other major appointments and professional qualifications; and (iv) does not have any relationship with any Directors, senior management or substantial or controlling Shareholders of the Company (as defined under the Rules Governing the Listing of Securities on the Stock Exchange (the "**Listing Rules**")).

As at the date of this announcement, Mr. GUO does not have any interest in the shares, underlying shares or debentures of the Company and/or its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed above, there are no other matters concerning Mr. GUO that need to be brought to the attention of the Shareholders, nor is there any information relating to Mr. GUO that is required to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Listing Rules.

The Board would like to express welcome to Mr. GUO for his appointment as the executive Director.

ELECTION OF THE CHAIRMAN OF THE BOARD

The Board is pleased to announce that the Board has elected Mr. GUO as the chairman of the Board, with effect from 17 July 2026.

CHANGE OF THE CHAIRMAN OF THE NOMINATION COMMITTEE AND THE STRATEGIC COMMITTEE

The Board hereby announces that Mr. GUO has been appointed as the chairman of each of the Nomination Committee and the Strategic Committee, with effect from 17 July 2026.

CHANGE OF AUTHORISED REPRESENTATIVE

The Board further announces that Mr. YANG has ceased to act as an authorised representative of the Company (the "**Authorised Representative**") under Rule 3.05 of the Listing Rules following his resignation, and Mr. GUO has been appointed as the Authorised Representative with effect from 17 July 2026.

By Order of the Board
China Traditional Chinese Medicine Holdings Co. Limited
LI Hongjian
Executive Director

Hong Kong, 17 July 2026

As at the date of this announcement, the Board comprises twelve Directors, of which Mr. GUO Jinhong, Mr. LI Hongjian and Mr. PENG Li are executive Directors; Mr. LI Xiangrong, Mr. ZU Jing, Ms. XU Jinghui, Mr. CHEN Kun and Mr. HUANG Hao are non-executive Directors; and Mr. XIE Rong, Mr. YU Tze Shan Hailson, Mr. QIN Ling and Mr. LI Weidong are independent non-executive Directors.